Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: June 2012

Second MDoutlook post-ASCO QP released – NSCLC and RCC

Pulsing its global MDoutlook network of over 62,000 cancer treaters, Arcas is the first organization presenting the clinical impact of new data presented at ASCO.

Focusing on key new data presented in Melanoma, Lung Cancer, Renal Cell Carcinoma, Prostate Cancer, Colorectal Cancer and Hepatocellular Carcinoma, we are distributing the results in 4 reports. Based on a total response of more than 400 cancer treaters from 22 countries, we are proud to present our analysis on the first three disease areas:
* MDoutlook ASCO 2012 QP – NSCLC+RCC
* MDoutlook ASCO 2012 QP – Melanoma

MDoutlook activities are predicated on 3 critical principles: 1) Relevant and accurate insight directly from pre-validated treaters; 2) Robust coverage and 3) Rapid response. Insight is presented in reports that can be shared directly with senior management, and intelligence is enhanced by the review and feedback from key ThoughtLeaders in each disease covered.

We continue our collaboration with our friends at Oncology Business Review (OBR) for distribution of this report; their Editor’s Blog has a copy of the results.

If you have any questions or would like to discuss how MDoutlook can support your oncology intelligence needs, please contact me directly.

Regards,
Jan Heybroek
President, The Arcas Group

First MDoutlook post-ASCO Quick Poll released – Melanoma

We want to thank you and your colleagues for submitting great questions for our series of MDoutlook Quick Polls directly post-ASCO. Pulsing its global network of >62,000 cancer treaters, MDoutlook has already received more than 400 completed surveys from more than 20 countries.

Focusing on key new data presented in Melanoma, Lung Cancer, Renal Cell Carcinoma, Prostate Cancer, Colorectal Cancer and Hepatocellular Carcinoma, we will be distributing the results in 4 reports. Follow this link for the first report: MDoutlook ASCO 2012 QP – Melanoma.

MDoutlook activities are predicated on 3 critical principles: 1) Relevant and accurate insight directly from pre-validated treaters; 2) Robust coverage and 3) Rapid response. Our post-ASCO Quick Polls have generated responses from more than 2,000 cancer treaters in 35 countries over the last 5 years, with insight delivered within 5 business days from fielding.

We continue our collaboration with our friends at Oncology Business Review (OBR) for distribution of this report; their Editor’s Blog has a copy of the results.

If you have any questions or would like to discuss how MDoutlook can support your oncology intelligence needs, please email me directly.

Regards,
Jan Heybroek
President, The Arcas Group